XX
 XX
 XX
 FA MEF-2
 XX
 SY MEF-2; MEF-2A; MEF2.

XX
 OS human, Homo sapiens
 OC eukaryota; animalia; metazoa;
chordata; vertebrata; tetrapoda; mammalia;
 OC eutheria; primates

XX
 HO D-MEF2 (Drosophila)
 XX
 CL C0014; MADS; 4.4.1.1.1.1.

XX
 SZ 507 AA; 54.8 kDa (cDNA)
 XX
 XX
 SC conceptually
translated from EMBL/GenBank/DDBJ #X68505
 XX
 FT 1 59 PF00319;
SRF-TF.
 FT 1 60 SM00432; MADS.
 FT 3 57 MADS box.
 FT
58 86 MEF2 domain.
 FT 87 132 replaced by 87-130 in aMEF-2.

FT 141 186 serine-/threonine-rich region (20/46).
 FT 289 296
absent in RSRFC4/RSRFC9.
 FT 312 312 threonine phosphorylation
site.
 FT 319 319 threonine phosphorylation site.
 FT 355
355 serin phosphorylation site.
 FT 420 446 glutamine-/proline-rich
region (27/27).
 XX
 SF alternative splicing leads to aMEF-2,
RSRFC4, RSRFC9;
 SF direct interaction with other myogenic
factors (bHLH proteins MyoD,
 SF myogenin, MRF4), but not with
E2 proteins [7];
 SF G2E mutant exhibits MCM1-binding specificity
[5];
 SF heterodimerization with MEF-2D [1];
 XX
 CP
cardiac, smooth, skeletal muscle, less in placenta, brain, lung,
kidney
 CP [8]; P19 cells differentiated into neurons or endodermal
cells,
 CP undifferentiated P19 cells [4]
 CN liver [8]

XX
 FF activator [8];
 FF involved in myogenesis [8] [6];

FF cooperates with myogenic bHLH factors through E-box for gene
activation in
 FF skeletal muscle cells [7];
 FF MADS domain
of MEF2A is both necessary and sufficient for binding to MyoD

FF [7];
 FF synergistic activation of transcription in neurogenic
lineages with MASH1
 FF [4];
 FF threonines 312 and 319
are phosphorylation sites for p38 [1] [2];
 FF serine 355 is
a phosphorylation site for p38 [2];
 FF phosphorylation of
MEF-2A in a MEF-2A/MEF-2D heterodimer enhances
 FF MEF-2-dependent
gene expression [1].;
 XX
 IN T01537; MRF4; mouse, Mus musculus.

IN T00525; MyoD; human, Homo sapiens.
 IN T00526; MyoD; mouse,
Mus musculus.
 IN T00528; myogenin; mouse, Mus musculus.

XX
 XX
 XX
 XX
 RN [1]; RE0015211.
 RX MEDLINE;
99077942.
 RA Zhao M., New L., Kravchenko VV., Kato Y., Gram
H., di Padova F., Olson E.
 RA N., Ulevitch R. J., Han J.

RT Regulation of the MEF2 family of transcription factors by p38

RL Mol. Cell. Biol. 19:21-30 (1999).
 RN [2]; RE0015225.

RX MEDLINE; 99303824.
 RA Ornatsky O. I., Cox D. M., Tangirala
P., Andreucci J. J., Quinn Z. A.,
 RA Wrana J. L., Prywes R.,
Yu Y. T., McDermott J. C.
 RT Post-translational control of
the MEF2A transcriptional regulatory protein
 RL Nucleic Acids
Res. 27:2646-2654 (1999).
 RN [3]; RE0004143.
 RX MEDLINE;
96104596.
 RA Fickett J. W.
 RT Quantitative discrimination
of MEF2 sites
 RL Mol. Cell. Biol. 16:437-441 (1996).
 RN
[4]; RE0015139.
 RX MEDLINE; 97059111.
 RA Black B.L., Ligon
K.L., Zhang Y., Olson E.N.
 RT Cooperative transcriptional
activation by the neurogenic basic
 RT helix-loop-helix protein
MASH1 and members of the myocyte enhancer factor-2
 RT (MEF2)
family
 RL J. Biol. Chem. 271:26659-26663 (1996).
 RN [5];
RE0004114.
 RX MEDLINE; 95349573.
 RA Nurrish S. J., Treisman
R.
 RT DNA binding specificity determinants in MADS-box transcription
factors
 RL Mol. Cell. Biol. 15:4076-4085 (1995).
 RN [6];
RE0010487.
 RX MEDLINE; 95257952.
 RA Naidu P. S., Ludolph
D. C., To R. Q., Hinterberger T. J., Konieczny S. F.
 RT Myogenin
and MEF2 function synergistically to activate the MRF4 promoter

RT during myogenesis
 RL Mol. Cell. Biol. 15:2707-2718 (1995).

RN [7]; RE0004142.
 RX MEDLINE; 95063991.
 RA Kaushal S.,
Schneider J. W., Nadal-Ginard B., Mahdavi V.
 RT Activation
of the myogenic lineage by MEF2A, a factor that induces and

RT cooperates with MyoD
 RL Science 266:1236-1240 (1994).

RN [8]; RE0000768.
 RX MEDLINE; 92387551.
 RA Yu Y.-T.,
Breitbart R. E., Smoot L. B., Lee Y., Mahdavi V., Nadal-Ginard
B.
 RT Human myocyte-specific enhancer factor 2 comprises a
group of
 RT tissue-restricted MADS box transcription factors

RL Genes Dev. 6:1783-1798 (1992).
 XX